These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 30245394)

  • 1. HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
    Sangwan R; Rajan R; Mandal PK
    Eur J Med Chem; 2018 Oct; 158():620-706. PubMed ID: 30245394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
    Qiu X; Zhu L; Wang H; Tan Y; Yang Z; Yang L; Wan L
    Bioorg Med Chem; 2021 Dec; 52():116510. PubMed ID: 34826681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural products as zinc-dependent histone deacetylase inhibitors.
    Tan S; Liu ZP
    ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of histone deacetylase as antitumor agents: A critical review.
    Manal M; Chandrasekar MJ; Gomathi Priya J; Nanjan MJ
    Bioorg Chem; 2016 Aug; 67():18-42. PubMed ID: 27239721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?
    Amin SA; Adhikari N; Jha T
    Pharmacol Res; 2017 Aug; 122():8-19. PubMed ID: 28501516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure-Activity Relationships.
    Poli G; Di Fabio R; Ferrante L; Summa V; Botta M
    ChemMedChem; 2017 Dec; 12(23):1917-1926. PubMed ID: 29117473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status in the discovery of dual BET/HDAC inhibitors.
    Ren Q; Gao W
    Bioorg Med Chem Lett; 2021 Jan; 31():127671. PubMed ID: 33229136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel inhibitors of human histone deacetylases: design, synthesis and bioactivity of 3-alkenoylcoumarines.
    Seidel C; Schnekenburger M; Zwergel C; Gaascht F; Mai A; Dicato M; Kirsch G; Valente S; Diederich M
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3797-801. PubMed ID: 25042254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update.
    Sultana F; Manasa KL; Shaik SP; Bonam SR; Kamal A
    Curr Med Chem; 2019; 26(40):7212-7280. PubMed ID: 29852860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for the design and synthesis of selective HDAC inhibitors.
    Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G
    Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress in the development of histone deacetylase inhibitors as anti-cancer agents.
    Zhang L; Lei J; Shan Y; Yang H; Song M; Ma Y
    Mini Rev Med Chem; 2013 Dec; 13(14):1999-2013. PubMed ID: 24160707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment.
    Stiborová M; Eckschlager T; Poljaková J; Hraběta J; Adam V; Kizek R; Frei E
    Curr Med Chem; 2012; 19(25):4218-38. PubMed ID: 22680633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Synthesis and activity of some new histone deacetylases inhibitors].
    Cheng YH; Guo YS; Han HZ; Wang N; Zhang GH; Guo ZR; Wu S
    Yao Xue Xue Bao; 2010 Jun; 45(6):735-41. PubMed ID: 20939182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
    Wahi A; Jain P; Sinhari A; Jadhav HR
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical Editing of Macrocyclic Natural Products and Kinetic Profiling Reveal Slow, Tight-Binding Histone Deacetylase Inhibitors with Picomolar Affinities.
    Kitir B; Maolanon AR; Ohm RG; Colaço AR; Fristrup P; Madsen AS; Olsen CA
    Biochemistry; 2017 Sep; 56(38):5134-5146. PubMed ID: 28858522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of class I HDAC modulators: Inhibitors and degraders.
    Huang Z; Zeng L; Cheng B; Li D
    Eur J Med Chem; 2024 Oct; 276():116696. PubMed ID: 39094429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies in developing promising histone deacetylase inhibitors.
    Zhang L; Fang H; Xu W
    Med Res Rev; 2010 Jul; 30(4):585-602. PubMed ID: 19634125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
    Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
    Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.